The Accad and Koka Report

Home | Mises Library | Andrew Althouse on Clinical Trial Design and Remdesivir

Andrew Althouse on Clinical Trial Design and Remdesivir

The Accad & Koka Report

Tags Health

05/08/2020Michel Accad, MDAnish Koka

Our guest is Andrew Althouse, statistician at the Center for Clinical Trials and Data coordination in Pittsburgh. He holds an undergraduate degree in Statistics and a PhD in Epidemiology from the University of Pittsburgh. His main area of interest is the design of randomized control trials. He discusses adaptive randomized control trials, and dissects the recent news of the positive Remdesivir trial.

Note: The views expressed on Mises.org are not necessarily those of the Mises Institute.
Authors:

Michel Accad, MD

Michel Accad, MD, practices cardiology and internal medicine in San Francisco, offering individualized care in a free-market setting. His blog about health care and medicine is AlertandOriented.com. He also co-hosts the Accad And Koa Report podcast.

Anish Koka

Anish Koka, MD, is a cardiologist in Philadelpia, Pennsylvania. His practice is Koka Cardiology. He co-hosts the Accad and Koa Report podcast.